Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3

Conditions

Immunoglobulin Light-chain Amyloidosis 3Amyloidosis 3

Interventions

Dexamethasone 21Calcium Dobesilate 10Melphalan 9Bortezomib 8Cyclophosphamide 7Lenalidomide 6pomalidomide 4miridesap 3daratumumab 3venetoclax 2ixazomib 2belantamab mafodotin 2Thalidomide 2Doxycycline 24-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene 2selinexor 1pegfilgrastim 1isatuximab 1dexamethasone acetate 1dexamethasone 21-phosphate 1carfilzomib 1birtamimab 1auricularum 1Vinorelbine 1Technetium Tc 99m Pyrophosphate 1Technetium 1Tacrolimus 1Surveys and Questionnaires 1Pharmaceutical Preparations 1Lisaftoclax 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Amyloidosis × miridesap × Clear all
NCT01777243 2018-07-24

A Study to Evaluate the Safety of GSK2398852 When Co-administered With GSK2315698 in Patients With Systemic Amyloidosis

GlaxoSmithKline

Phase 1 Completed
25 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

NCT01406314 2017-06-09

SAP Depleter Dose Assessment Study in Patients

GlaxoSmithKline

Phase 1 Completed
17 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

NCT02953808 2017-01-19

Phase 1 Study of GSK2315698 in Healthy Japanese Subjects

GlaxoSmithKline

Phase 1 Completed
18 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡